Docetaxel for prostate cancer: Best timing and right patient

Date

09 Oct 2016

Session

Multimodality treatment for hormone-naïve metastatic prostate cancer

Presenters

Nick James

Authors

N. James

Author affiliations

  • Cancer And Genomic Sciences, University of Birmingham, B15 2TT - Birmingham/GB
More

Resources

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings